Lexeo Therapeutics (LXEO) Cash from Operations (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Cash from Operations of 21144000.0 for Q1 2026, down 5.3% sequentially from 20079000.0 in Q4 2025, and up 2.63% YoY from 20601359.66 in Q1 2025.
Lexeo Therapeutics (LXEO) Cash from Operations (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Cash from Operations for 5 years, with the latest figure at 21144000.0 in Q1 2026.
- Quarterly Cash from Operations rose 2.63% year-over-year to 21144000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 97989000.0 (down 11.35% YoY) and the FY2025 annual result came in at 98561000.0, down 21.45% from the prior year.
- Cash from Operations eased to 21144000.0 in Q1 2026 per LXEO's latest filing, from 20079000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 13192000.0 in Q2 2023 and troughed at 29547000.0 in Q3 2025.
- A 5-year average of 19784142.86 and a median of 19226500.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations sank 102.6% in 2024, then gained 29.11% in 2025.
- Over 5 years, Cash from Operations stood at 16626000.0 in 2022, then grew by 15.91% to 13981000.0 in 2023, then slumped by 102.6% to 28326000.0 in 2024, then increased by 29.11% to 20079000.0 in 2025, then fell by 5.3% to 21144000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 21144000.0, 20079000.0, and 29547000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | -17.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.60 Mn |
| Jun 30, 2026 | -17.60 Mn |
| Mar 31, 2026 | -21.14 Mn |
| Mar 31, 2026 | -21.14 Mn |
| Dec 31, 2025 | -20.08 Mn |
| Dec 31, 2025 | -20.08 Mn |
| Sep 30, 2025 | -29.55 Mn |
| Sep 30, 2025 | -29.55 Mn |
| Jun 30, 2025 | -27.22 Mn |
| Jun 30, 2025 | -27.22 Mn |
| Mar 31, 2025 | -21.72 Mn |
| Mar 31, 2025 | -21.72 Mn |
| Dec 31, 2024 | -28.33 Mn |
| Dec 31, 2024 | -28.33 Mn |
| Sep 30, 2024 | -17.81 Mn |
| Sep 30, 2024 | -17.81 Mn |
| Jun 30, 2024 | -20.15 Mn |
| Jun 30, 2024 | -20.15 Mn |
| Mar 31, 2024 | -14.87 Mn |
| Mar 31, 2024 | -14.87 Mn |